Kornimate/medical-research-clean huggingface dataset:
sexual function in patients suspected of non-muscle invasive bladder cancer

Conditions: Urinary Bladder Neoplasms; Sexual Dysfunction, Physiological; Sexual Dysfunctions, Psychological; Erectile Dysfunction; Hematuria

Summary: the purpose of the study is to investigate sexual function in patients suspected of non muscle invasive bladder cancer (nmibc). the investigators hypothesis is that reduced sexual function is underdiagnosed in patients with non-muscle invasive bladder cancer and that active examination and treatment may worsen the sexual function.


Eligibility criteria:
inclusion criteria: * patients with primary hematuria, both gross and microscopic * men and women older or equal to 40 years of age * signed informed consent statement exclusion criteria: * men and women younger than 40 years of age * patients with recurrent hematuria and known causative disease * already known urogenital cancer * previous massive pelvic surgery or pelvic radiotherapy * tur-p within the last 2 months * participants diagnosed with tumors originating from the ureters, renal pelvis and kidney, and bladder tumors at t stage more than or equal to t1b.
a study to evaluate the long-term safety and efficacy of paltusotine for the treatment of acromegaly (acrobat advance)

Conditions: Acromegaly

Summary: a phase 2, open label, long-term extension study designed to evaluate the safety and efficacy of paltusotine (formerly crn00808; an oral selective nonpeptide somatostatin receptor type 2 biased agonist) in subjects with acromegaly.


Eligibility criteria:
inclusion criteria: 1. completed one of the parent studies (acrobat evolve \[crn00808-02\] or acrobat edge \[crn00808-03\]) 2. females must be non-pregnant and non-lactating, and either surgically sterile, post-menopausal, or using effective method(s) of birth control 3. willing to provide signed informed consent exclusion criteria: 1. clinically significant concomitant disease including, but not limited to, cardiovascular disease; moderate or severe renal insufficiency; or significant liver disease (including cirrhosis) 2. pituitary radiation since completing participation in parent studies 3. history or presence of malignancy except adequately treated basal cell and squamous cell carcinomas of the skin within the past 5 years 4. positive test at screening for hiv, hepatitis b surface antigen (hbsag) or hepatitis c antibody (hcv-ab). 5. history of alcohol or substance abuse in the past 12 months 6. use of any investigational drug (other than paltusotine) within the past 30 days or 5 half-lives, whichever is longer before screening 7. any condition that in the opinion of the investigator would jeopardize the subject's appropriate participation in this study. 8. cardiovascular conditions or medications associated with prolonged qt or those which predispose subjects to heart rhythm abnormalities 9. subjects with symptomatic cholelithiasis 10. subjects with clinically significant abnormal findings during the screening period, and any other medical condition(s) or laboratory findings that, in the opinion of the investigator, might jeopardize the subject's safety or ability to complete the study

Keywords: acromegaly acrobat advance paltusotine
phase 2 study of ipilimumab plus dacarbazine in japanese patients with advanced melanoma

Conditions: Melanoma

Summary: the purpose of this study is to determine the survival rate after 1 year of treatment with ipilimumab plus dacarbazine in patients with previously untreated stage iii (unresectable) or stage iv melanoma.


Eligibility criteria:
key inclusion criteria: * japanese patients with histologic diagnosis of malignant melanoma * previously untreated stage iii with n3 (unresectable) or stage iv melanoma * prior adjuvant melanoma therapy permitted * eastern cooperative oncology group performance status of 0 or 1 * life expectancy of at least 16 weeks in this study * adequate bone marrow and renal and hepatic function, specifically: * white blood cell count ≥2500/ul, absolute neutrophil count ≥1000/ul, platelet count ≥75,000/ul, hemoglobin level ≥9.0 g/dl, creatinine level ≤2.5\*upper limit of normal (uln), aspartate transaminase/alanine transaminase level \<2.5\*uln for patients without liver metastasis and \<5\*uln for patients with liver metastasis, total bilirubin level \<1.5\*uln (for those with gilbert's syndrome, lower than 3.0 mg/dl) key exclusion criteria: * evidence of brain metastases on brain imaging * active brain metastases with symptoms or requiring corticosteroid treatment; patients with any other malignancy from which they have been disease-free for fewer than 5 years, with the exception of adequately treated and cured basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix * primary ocular or mucosal melanoma * history of or current active autoimmune disease * history or concurrent disease of gastrointestinal perforations * hiv infection; active hepatitis b or c or human t-lymphotropic virus type1 infection, based on testing performed during the screening period of this study * prior or concomitant therapy with any anticancer agent for melanoma, or other investigational anticancer therapies * prior adjuvant therapy \<4 weeks prior to the start of study drug administration * concomitant therapy with immunosuppressive agents, surgery, or radiotherapy * prior treatment with ctla-4 inhibitors/agonists or other experimental immunotherapy drugs * treatment with other investigational products within 4 weeks prior to initial treatment of study drug
virtual reality and guided imagery to reduce procedural pain

Conditions: Pain Management; Virtual Reality Pain Distraction; Guided Imagery; Peripheral Intravenous Catheterization Application

Summary: aim: the aim of the present study was to examine the effect of virtual reality and guided imagery to reduce pain during peripheral intravenous catheterization procedures in adults.methods: the study will include 90 adults who were randomly selected between february and march 2025. one application group (n=30) will receive a virtual reality glasses application; the other application group (n=30) will receive a guided imagery application. the applications to the site of the peripheral intravenous catheterization will last two minutes. the control group (n=30) will receive the standard peripheral intravenous catheterization application procedure. the groups' level of pain during catheterization will be assessed using a visual analog scale.


Eligibility criteria:
inclusion criteria: * being in accordance with time and place * being in no sensory problems * being aged between 18 and 65 years * being able to evaluate the visual analog scale correctly * participating voluntarily in the research. exclusion criteria: * not participating voluntarily in the research * not fitting the inclusion criteria of the research * having a vision or hearing problem * having any illness which could affect pain perception, such as sensorymotor disorder, diabetes, peripheral vascular diseases or peripheral neuropathy * having phlebitis, scar tissue, dermatitis, an incision or findings of infection at the place where the intervention was to be performed * having taken an analgesic (within the previous six hours) or an anesthetic agent before the peripheral intravenous catheterization procedure

Keywords: virtual reality guided imagery pain management peripheral intravenous catheterization
dendritic cells(dc)-based id vaccination in stage-i myeloma

Conditions: Multiple Myeloma; Plasmocytoma

Summary: patients with stage-i multiple myeloma are treated with a vaccine made from their own immune cells (dendritic cells) and their own myeloma protein. vaccinations are given on 5 occasions every 4 weeks. the aim is to induce an immune reaction against the malignant myeloma cells in order to slow down or cure the disease.


Eligibility criteria:
inclusion criteria: * multiple myeloma * stage i (salmon \& durie) * no cytoreductive pre-treatment exclusion criteria: * myeloma stages ii-iii * asecretory disease

Keywords: dendritic cells (dc) idiotype (id) immunotherapy
articaine 4% versus lidocaine 2% for local anesthesia of mih-affected maxillary molars

Conditions: Molar Incisor Hypomineralisation

Summary: comparison of injection pain with lidocaine and articaine. comparison of the efficacy of lidocaine and articaine during treatment of mih- maxillary molars. design: a randomized, controlled, crossover, triple-blinding clinical study including twenty six cooperative children, aged 6-12years old

background and aims: some dentists have difficulty obtaining effective anesthesia when treating mih molars. there are no studies comparing the effectiveness of lidocaine and articaine in mih-maxillary molars. design: a randomized, controlled, crossover, triple-blinding clinical study including twenty six cooperative children , aged 6-12 years old. each child was randomly assigned to either articaine 4% or lidocaine 2% in their first session with the second solution being used at the second session.

Eligibility criteria:
inclusion criteria: * absolute positive or positive behavior according to the frankel scale. * child is not under the effect of any analgesics or sedatives and their weight was more than 20 kg. * healthy, both physically and mentally * a child with a mih-affected maxillary permanent first molar on the right and left sides . exclusion criteria: * children who are uncooperative * allergic anesthetics used in the study * children who show inflammation in the injection site.

Keywords: local anesthesia lidocaine 2% articaine 4% molars
sleep headphones and hdu: a novel intervention and sound evaluation

Conditions: Sleep Deprivation; Sleep

Summary: it is well established that patients sleep poorly in the intensive care unit (icu), and excessive noise is considered to be a modifiable cause of this. previous studies have tried to reduce ambient noise by educating staff and fixing noisy equipment. other studies have tried to reduce the noise experienced by patients by supplying them with active noise cancelling headphones and earplugs. in this study we are combining active noise cancelling headphones with white noise to try and reduce noise experienced by patients, with the aim of improving their sleep. sleep deprivation is known to negatively impact health, and so improving sleep may improve patient outcomes as well as improve the patient's experience in critical care. the investigators will screen all patients in the critical care wards in the royal infirmary of edinburgh. patients that are receiving ventilation, are delirious or have already been enrolled in the study will be excluded. after allowing patients to give informed consent, we will randomise them into one of two study groups: study group a will receive standard care on the 1st night (no headphones), and will receive the intervention (active noise cancelling headphones with white noise) on the 2nd night. study group b will receive the intervention on the 1st night, and will receive standard care on the 2nd night. all patients will wear a xiaomi miband 2 wrist band, that tracks movement and sleep. patients will fill in the pittsburgh sleep quality index at the beginning of the study to establish usual sleeping habits. our primary outcome measure is the mean score on the richard campbell sleep questionnaire (rcsq), which will be filled in by the patient the morning after each night. our secondary outcome measure is the data from the wrist band, noise levels measured overnight, and patient experience of the intervention.


Eligibility criteria:
inclusion criteria: * critical care patient in royal infirmary of edinburgh exclusion criteria: * \< 18 years of age * if the patient is delirious. this will be clarified by asking the nurses, who use the confusion assessment method for the icu (cam-icu) score. * if the patient is receiving any form of ventilation (invasive or non-invasive ventilation, continuous positive airway pressure (cpap), high flow nasal oxygen (hfno) or respiratory support at night) * physical reasons why they can't wear over-ear headphones * pre-existing severe hearing impairment * previous participation in the study. * if the patient is likely to receive medical interventions during the night that would disturb their sleep. * patients expected to leave the critical care wards within the following 48hours. * refusing consent or inability to give consent.

Keywords: critical care patients high dependency unit intensive care unit
comparative analysis of injectable anticoagulants for thromboprophylaxis post cancer-related surgery

Conditions: Thrombosis, Venous

Summary: venous thromboembolism (vte), including deep vein thrombosis (dvt) and pulmonary embolism (pe), is a common post-operative complication. the effectiveness of fondaparinux compared with other injectable anticoagulants in vte following major orthopedic and abdominal surgery has been evaluated in database studies; however, the effectiveness of injectable anticoagulant medications following cancer-related surgeries in the practice setting has not been as well documented. the objective of this study is to analyze patient records from a national hospital database and compare the outcomes and costs between four types of injectable anticoagulant medications that were prescribed for the prevention of vte following cancer-related surgery. this analysis will assess and quantify the outcomes, resource utilization, and cost of care for patients receiving fondaparinux, enoxaparin, dalteparin or unfractionated heparin. the outcomes of interest include the occurence of vte, rates of major bleeds, medical resource utilization, and total costs (medical plus pharmacy). the source of data for this study is the premier perspective database™. this hospital claims database links de-identified inpatient medical, pharmacy, and billing data from more than 500 hospitals. this study is a retrospective cohort study that uses propensity score matching to adjust for the differences between the numbers of patients treated with each medication.


Eligibility criteria:
inclusion criteria: * age 18 and older * at least one record of a primary inpatient discharge diagnosis of cancer (index hospitalization) * a procedure code for a cancer-related surgery during the index hospitalization * a code for an anticoagulant treatment (dalteparin, enoxaparin, fondaparinux or unfractionated heparin (ufh)) as thromboprophylaxis therapy during the day prior to or two days after cancer-related surgery during the index hospitalization (this is the index event) exclusion criteria: * a record that the patient received more than one injectable anticoagulant on day 1 of anticoagulant therapy * a record that the patient received anticoagulant therapy prior to index anticoagulant * a primary diagnosis code of dvt, pe, or major bleed * evidence of an outpatient emergency department or hospital outpatient clinic visit that included a diagnosis code for dvt or pe during the 6 months prior to the index hospitalization * patient records for patients transferred from another facility outside premier system on index hospitalization

Keywords: cancer surgery venous thromboembolism hospitalization anticoagulants costs and cost analysis thromboprophylaxis
inst 0603c patients with unresectable/metastatic pancreatic cancer treated in the unm cancer

Conditions: Pancreatic Cancer

Summary: chart review of patients with pancreatic cancer treated with combination of irinotecan, oxaliplatin and cetuximab.

chart review to describe the clinical outcomes in patients pancreatic cancer treated with combination of irinotecan, oxaliplatin and cetuximab.

Eligibility criteria:
inclusion criteria: patients with unresectable/metastatic pancreatic cancer treated in the unm cancer research and treatment center. exclusion criteria: not specified.
normative data of dynamic gait index and 5 time sit to stand test among elderly population

Conditions: Fall; Old Age; Debility

Summary: the goal of this observational study is to measure the normative data for dynamic gait index and 5 time sit to stand test in elderly population. this study aimed for to take normative measurement of dynamic gait index and five time sit to stand test among elderly population and to compare the preliminary values of above mentioned tests with age.

anthropometric factors affect the stability limits of the individual and can affect the motor strategies relating to balance control. the core elements of anthropometry are height, weight, body mass index (bmi), body circumferences (waist, hip, and limbs), and skin-fold thickness. some anthropometric variables, such as body mass, are directly related to postural balance. due to lack of normative data for dynamic gait index and five times sit to stand test in elderly population, this study aimed to formulate normative values for dynamic gait index and five times sit to stand test among elderly and correlation with anthropometric measures. objectives: the objective of this study was to take normative measurement of dynamic gait index and five times sit to stand test among elderly population and to compare the preliminary values of above mentioned tests with age. all possible elder population was taken in current study to calculate the normative values of these two tests, five times sts to measure the ability to get up from a chair and dgi to record dynamic gait tasks in elder people

Eligibility criteria:
inclusion criteria: * 45-60 years elderly population. * both male and female were included in given age group. * older adults ambulate without a device or assistance. * population who has no deformity will be included. exclusion criteria: * older adults who cannot ambulate were excluded * pregnant females were excluded from this study * population having any deformities was not included in this study. * any participants suffering from malignancy, infection or taking anticoagulant therapy were also excluded.

Keywords: anthropometrics dgi five time sit to stand test
an imaging study in patients with thyroid cancer or head and neck cancer with pertechnetate made in a cyclotron (c-pert)

Conditions: Thyroid Neoplasms; Head and Neck Neoplasms

Summary: doctors at the cross cancer institute have developed a new method of producing 99mtc pertechnetate in a cyclotron unit. a study done at the cross cancer institute in 2011 with ten patients using this imaging agent showed that it was safe and produced images with the same pattern as generator produced pertechnetate. this study is now being done in larger numbers of patients to again show that the imaging pattern of both agents is the same, and to again demonstrate its safety.

to demonstrate the efficacy of cyclotron-produced tc-99m pertechnetate (c-pert; manufactured by the edmonton pet centre/erc) in comparison to generator-produced tc-99m pertechnetate (g-pert; from approved commercial source; using qualitative and quantitative clinical imaging biodistribution data.

Eligibility criteria:
inclusion criteria: * thyroid cancer, or * head and neck cancer for salivary gland transfer * age 18-79 * biochemical parameters \< 5x uln * wbc \> 3.0/ul * anc \> 1.5/ul * platelets \> 75,000/ul * hemoglobin \> 10 g/dl * karnofsky 50-100 exclusion criteria: * nursing or pregnant females * \ 79 years * uncontrolled asthma * acute iritis * narrow angle glaucoma * previous radiation to head/neck

Keywords: 99mtc pertechnetate thyroidectomy thyroid neoplasms
the non-optical resect and discard study (nord)

Conditions: Polyp of Colon

Summary: eliminating the need for conventional histopathological assessment of diminutive colon polyps - the non-optical resect and discard (nord) study

implementation of this approach by community-based gastroenterologists has failed to reach the required quality benchmarks and studies evaluating optical biopsy have not shown diagnostic test performance results that meet standards set by society guidelines in order to promote its widespread clinical adoption. optical polyp diagnosis and the current resect and discard approach are too complex for clinical adoption. thus, clinical implementation of this valuable concept has not been achieved to date and its cost-saving potential has not been realized. in order to effectively operationalize a resect and discard strategy, one must find a different way to distinguish neoplastic from non-neoplastic polyps. there exist differences in the proportion of polyps found to be adenomatous in the left and right colon. one recent study reported that 30% of left-sided polyps and 76% of right-sided polyps were found to be adenomas on histology. since polyps located in the proximal colon are more likely to be adenomas and polyps in the recto-sigmoid colon are more likely hyperplastic we hypothesized that a model based on polyp location might be able to replace optical biopsy and histopathology. such an approach would be very simple to adopt by every clinician and would allow for easy adoption into clinical practice.

Eligibility criteria:
inclusion criteria: * signed informed consent form * age 45 to 80 years * indication for full colonoscopy exclusion criteria: * known inflammatory bowel disease * active colitis * coagulopathy * familial polyposis syndrome * poor general health defined as an asa class \> 3 * emergency colonoscopies.

Keywords: polyp resection colorectal cancer
study to evaluate safety of brimonidine/timolol fixed combination in glaucoma or ocular hypertension patients

Conditions: Glaucoma; Ocular Hypertension

Summary: this study evaluates the safety of brimonidine/timolol fixed combination in glaucoma or ocular hypertension patients


Eligibility criteria:
inclusion criteria: * diagnosis of ocular hypertension or glaucoma * patient requires iop-lowering therapy in both eyes exclusion criteria: * uncontrolled medical conditions * contraindication to β-adrenoceptor antagonist therapy or brimonidine therapy